From GlobeNewswire:

Fractyl Health announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, totaling approximately $110.0 million. The company granted the underwriters a 30-day option to purchase up to an additional 1,099,999 shares of its common stock at the initial public offering price less underwriting discounts and commissions. Fractyl Health’s common stock is expected to start trading on the Nasdaq Global Market on February 2, 2024, under the ticker “GUTS.”

Fractyl Health, a metabolic therapeutics company focused on treating type 2 diabetes (T2D) and obesity, plans to use the proceeds from its initial public offering to further its goal of pioneering new approaches to treating metabolic diseases.

A registration statement for this offering has been declared effective by the U.S. Securities and Exchange Commission on February 1, 2024, and the offering is being made only by means of a prospectus available from BofA Securities, Morgan Stanley & Co. LLC, and Evercore Group L.L.C. Fractyl Health emphasized that this press release is not an offer to sell, or a solicitation of an offer to buy its shares.

Fractyl Health urged prospective investors to be mindful of forward-looking statements included in its disclosures, emphasizing the inherent uncertainties and risks associated with investing. The company offered corporate, media, and investor contacts for further information on the offering.



Read more: Fractyl Health Announces Pricing of Initial Public